Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$229.02
pos +0.00
+0.00%
Today's Range: 229.00 - 235.30 | BIIB Avg Daily Volume: 1,796,000
Last Update: 06/24/16 - 4:00 PM EDT
Volume: 0
YTD Performance: -25.16%
Open: $0.00
Previous Close: $238.62
52 Week Range: $242.07 - $420.99
Oustanding Shares: 219,051,491
Market Cap: 52,270,066,782
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 10 10
Moderate Buy 2 2 2 2
Hold 5 6 8 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.72 1.79 1.88 1.88
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 15.60
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
15.60 14.70 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-9.98% -44.23% 14.38%
GROWTH 12 Mo 3 Yr CAGR
Revenue 10.80 0.90 0.25
Net Income 22.20 1.60 0.37
EPS 24.00 1.60 0.38
Earnings for BIIB:
EBITDA 4.28B
Revenue 9.42B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $4.69 $4.76 $19.01 $20.25
Number of Analysts 18 18 18 18
High Estimate $5.29 $5.33 $20.80 $22.70
Low Estimate $4.46 $4.54 $18.40 $18.89
Prior Year $4.22 $4.48 $17.01 $19.01
Growth Rate (Year over Year) 11.11% 6.20% 11.79% 6.47%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
The federal government has turned violently against these deals.
A lost leader in Celgene and a Perrigo rumor have put a scare in the charts.
This is the group that is the most dangerous politically.
U.S. indices are in the green Wednesday as commodities gain. 
Bearish
Jun 08, 2016 | 7:29 AM EDT
BIIB was downgraded to Neutral, Citigroup said. $295 price target. Removing Lingo from the model, given poor clinical trials. 
Too many turn bearish too quickly just because they can't find any entry points.
Big move for biotechs isn't pleasant.
U.S. indices are up as oil continues its climb past $50 a barrel.
We've seen yet another disaster in Biogen's history of overpromising and under-delivering.
These mid-caps would do well by themselves, but could tempt bigger companies.

Columnist Conversations

.... that Monday is a total bloodbath.
I was going to publish a thought piece on Pandora and Groupon for the weekend; but it will get lost with all o...
Clorox is trading at new all time highs today with the help of a nice bump in trade.  The stock is up just ov...
Spot Gold has hurdled-- and is sustaining above-- its prior significant rally peak at $1307.40, which has the ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.